Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
EVP Chief R&D · ALNYLAM PHARMACEUTICALS, INC. · Common Stock
Open-market sale
$18K reported value · 0.2% of prior position
Disclosed 2 business days after execution (deadline: 2)
First recorded trade by this actor in this security
4 other actors traded the same direction within 14 days
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 16 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $72K 197 sh | Jan 14, 2026 traded Jan 13, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $15K 41 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $5,667 15 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 19 | Tanguler TolgaEVP, Chief Commercial Officer | Grant or award | A | — 3,800 sh | Jan 14, 2026 traded Jan 11, 2026 | |
| 23 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $73K 199 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $15K 40 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $7,137 19 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 39 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $80K 220 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | Open-market sale | SELL | $96K 261 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | Open-market sale | SELL | $13K 34 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $35K 98 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $17K 47 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 20 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $34K 92 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 16 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Open-market sale · 10b5-1 plan | SELL | $104K 280 sh | Jan 14, 2026 traded Jan 13, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $15K 41 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 9 | Fitzgerald Kevin JosephCSO & EVP, Head of Research | Grant or award · 10b5-1 plan | A | — 3,800 sh | Jan 14, 2026 traded Jan 11, 2026 | |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | Open-market sale | SELL | $35K 98 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $35K 98 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $44K 123 sh | Jan 14, 2026 traded Jan 12, 2026 | |
| 36 | Garg PushkalEVP Chief R&D | Open-market sale | SELL | $7,137 19 sh | Jan 14, 2026 traded Jan 12, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $18,321
Garg Pushkal filed this Form 4 reporting a open-market sale of ALNY on Jan 12, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.